Tremfya shows durable efficacy in plaque psoriasis

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported two-year data from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya guselkumab on Saturday showing that the drug maintained long-term efficacy in patients with moderate-to-severe plaque psoriasis.

In the 837-patient trial, 82.1% of patients who received subcutaneous Tremfya at weeks zero and four and then every eight weeks for 100 weeks had 90% skin clearance as measured by the Psoriasis Area and Severity Index (PASI 90). Additionally, 82.4% of patients achieved an Investigator’s Global Assessment (IGA) score of cleared or minimal disease at week 100...